Notice



Notice reference number: 1618.15.12 Notice date: 21/12/2015 What's this about? Effective date: 21/12/2015 **ASX Trade** ASX 24 ASX TECH Trading Clearing Settlement ALC ASX NET Market Data Other Operations Technology Rules Compliance Risk Title AFT Pharmaceuticals Limited – Admission and Commencement of Official Quotation **Description** AFT Pharmaceuticals Limited (ASX Code: AFP) (the "Company") is expected to be admitted to the official list of ASX Limited ("ASX") on Monday, 21 December 2015 as an ASX Foreign Exempt Listing. Official Quotation of the Company's securities will commence at 12.00 pm AEDT on Tuesday, 22 December 2015. The Company raised NZ\$35,638,192.80 pursuant to the offer under its replacement product disclosure statement dated 1 December 2015, by the issue of 11,656,498 ordinary fully paid shares at an issue price of NZ\$2.80 per share and the sale of 1,071,428 ordinary fully paid shares at a sale price of NZ\$2.80 per share. As an ASX Foreign Exempt Listing, the Company is primarily regulated by the listing rules of its home exchange (being the NZX Limited, stock code: AFT) **Quoted Securities:** 96,834,839 fully paid ordinary shares ASX Code: AFP Time: 12.00pm AEDT Date: 22 December 2015 **ASX Trade Abbreviation: AFT PHARM** ISIN: NZAFTE0001S4 Home Branch: Sydney **Industry Classification: TBA** Registered Office: Level 1, Neilson Building 129 Hurstmere Road, Takapuna, Auckland, New Zealand Agent for Service of Process: Australian Company Secretaries Pty Ltd, Suite 806, level 8, 70 Pitt Street Sydney NSW 2000 Company Secretary/ASX Contact: Malcolm Tubby +64 9488 0232

Malcolm@aftpharm.com

ASX Notice (continued)

Share Registry: Computershare Investor Services Limited

Level 2, 159 Hurstmere Road, Takapuna, Auckland 0622

Balance Date: 31 March

CHESS: Participating. The Company will also operate an issuer sponsored subregister.

Place of Incorporation: New Zealand

Dividend Policy: Refer Company disclosures

Activities: The Company is a growing multinational pharmaceutical business with a broad range of

products, both developed itself and in-licensed from third parties. The Company's products cover all major pharmaceutical distribution channels: over-the-counter, prescription and

hospital.

What do I need to do and by when?

Instructions

For further details refer to the Company's replacement product disclosure statement dated 1 December 2015.

Need more information?

Refer above contact details for the Company.

<u>Issued by</u> Kate Kidson

Contact Details (03) 9617 8772

Disclaimer